19 studies found for:    "gene therapy" OR "gene transfer" OR "virus delivery" | plasmid
Show Display Options
Rank Status Study
1 Completed Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial
Condition: Coronary Artery Disease
Intervention: Genetic: intramyocardial injection of VEGF-A165/bFGF:placebo plasmid
2 Completed The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris
Condition: Ischemic Heart Disease
Intervention: Genetic: VEGF-A165 plasmid
3 Completed Gene Therapy of Pancreatic Ductal Adenocarcinoma
Condition: Gene Therapy in Pancreatic Adenocarcinoma
Intervention: Genetic: Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes
4 Completed Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Condition: Critical Limb Ischemia
Interventions: Genetic: VM202;   Other: Normal Saline
5 Recruiting A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Conditions: Critical Limb Ischemia;   Vascular Diseases;   Peripheral Arterial Disease
Intervention: Genetic: HGF Plasmid
6 Terminated Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
Condition: Metastatic Malignant Neoplasm
Intervention: Drug: Plasmid AMEP
7 Completed Trial of VLTS-589 in Subjects With Intermittent Claudication
Conditions: Intermittent Claudication;   Peripheral Vascular Disease
Intervention: Genetic: Plasmid based Gene Transfer product-VLTS-589
8 Unknown  Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Conditions: Ischemia;   Pathologic Processes
Interventions: Genetic: NL003;   Other: Normal Saline
9 Completed EW-A-401 to Treat Intermittent Claudication
Conditions: Intermittent Claudication;   Arteriosclerosis
Interventions: Drug: DNA Plasmid Vector;   Drug: EW-A-401 DNA Plasmid Vector
10 Recruiting Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy;   Other: laboratory biomarker analysis
11 Recruiting Study of a DNA Immunotherapy to Treat Melanoma
Condition: Malignant Melanoma
Intervention: Biological: SCIB1
12 Completed Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: gene therapy;   Biological: interleukin-2 gene;   Drug: methotrexate
13 Active, not recruiting Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
Condition: Painful Diabetic Neuropathies
Interventions: Genetic: Low Dose: 16 mg VM202;   Genetic: High Dose: 32 mg VM202;   Genetic: Placebo (Normal Saline)
14 Completed Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
Conditions: Leukemia;   Leukemia, B-Cell, Chronic
15 Completed A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Conditions: Breast Cancer;   Ovarian Cancer;   Prostate Cancer;   Colon Cancer;   Renal Cancer
Intervention: Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
16 Completed Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions
Condition: Peripheral Vascular Diseases
Interventions: Biological: riferminogene pecaplasmid;   Biological: Placebo (for riferminogene pecaplasmid)
17 Recruiting A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Condition: Colorectal Cancer
Intervention: Drug: EGEN-001-301
18 Withdrawn Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: Ad-REIC/Dkk-3
19 Unknown  Single Dose of pGM169/GL67A in CF Patients
Condition: Cystic Fibrosis
Intervention: Drug: pGM169/GL67A

Indicates status has not been verified in more than two years